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Not all of the mysteries of life lie in our genetic code. Some can be found buried in
our membranes. These shells of fat, sculpted in the central nervous system into the
cellular (and subcellular) boundaries of neurons and glia, are themselves complex systems
of information. The diversity of neural phospholipids, coupled with their chameleon-like
capacity to transmute into bioactive molecules, provides a vast repertoire of immediate
response second messengers. The effects of compositional changes on synaptic function
have only begun to be appreciated. Here, we mined 29 neurolipidomic datasets for
changes in neuronal membrane phospholipid metabolism in Alzheimer’s Disease (AD).
Three overarching metabolic disturbances were detected. We found that an increase
in the hydrolysis of platelet activating factor precursors and ethanolamine-containing
plasmalogens, coupled with a failure to regenerate relatively rare alkyl-acyl and alkenyl-acyl
structural phospholipids, correlated with disease severity. Accumulation of specific
bioactive metabolites [i.e., PC(O-16:0/2:0) and PE(P-16:0/0:0)] was associated with
aggravating tau pathology, enhancing vesicular release, and signaling neuronal loss.
Finally, depletion of PI(16:0/20:4), PI(16:0/22:6), and PI(18:0/22:6) was implicated in
accelerating Aβ42 biogenesis. Our analysis further suggested that converging disruptions
in platelet activating factor, plasmalogen, phosphoinositol, phosphoethanolamine (PE),
and docosahexaenoic acid metabolism may contribute mechanistically to catastrophic
vesicular depletion, impaired receptor trafficking, and morphological dendritic deformation.
Together, this analysis supports an emerging hypothesis that aberrant phospholipid
metabolism may be one of multiple critical determinants required for Alzheimer disease
conversion.
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NEUROLIPIDOMICS: CATALOGING FUNCTIONAL DIVERSITY
IN MEMBRANE BIOLOGY
The field of neurolipidomics seeks to understand how dynamic
changes in membrane composition regulate brain cell function.
Here, we mined 29 different neurolipidomic datasets generated
by 11 independent laboratories for critical changes in neural
membrane phospholipid metabolism (Tables S1–S4). We then
asked how these changes might mechanistically contribute to
synaptic dysfunction in Alzheimer’s Disease (AD). Neuronal
membranes are enriched in sterols, sphingolipids, glycerolipids,
and phospholipids (Figure 1A). Phospholipids are the most
abundant. Their assembly into lipid bilayers, with polar head
groups aligning at aqueous interfaces and hydrophobic carbon
chains buried within, produces the semi-permeable barri-
ers of cellular (and subcellular) membranes (Figures 1B,C).
These bilayers are often conceptualized as undulating fields
of identical molecules (Figure 1C). In fact, they are com-
plex matrices of several hundred molecularly distinct species
(Figure 2A). Composition is in constant flux. Carbon chains
and defining polar head groups are dynamically exchanged
by activated phospholipases and lysophospholipid transferases
in response to environmental stimuli (Figures 1D, 2B).
Until recently, this diversity has remained largely under-
appreciated and functional significance unexplored. However, for
the first time, significant technological advances in high per-
formance liquid chromatography (LC), electrospray ionization
(ESI), and matrix-assisted laser desorption ionization (MALDI)
mass spectrometry (MS) are enabling membrane composition
to be profiled comprehensively at the molecular level1. Coupled
with subcellular fractionation and careful consideration of extrac-
tion protocols that enrich for different phospholipid families,
1A number of excellent reviews have been recently published critically assess-
ing these technological milestones in neurolipidomics (Power and Patel, 2004;
Han, 2007, 2010; Piomelli et al., 2007; Hou et al., 2008; Astarita et al., 2009;
Brown and Murphy, 2009; Lindner and Naim, 2009; Blanksby and Mitchell,
2010; Bou Khalil et al., 2010; Niemoller and Bazan, 2010; Shevchenko and
Simons, 2010; Astarita and Piomelli, 2011; Wood, 2012).
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FIGURE 1 | Synaptic membrane remodeling. (A) Chemical
neurotransmission occurs at the synapse. (B) Neurotransmitters,
released into the synaptic cleft following fusion of vesicular with
pre-synaptic plasma membranes, interact with receptors shuttled along
the plasma membrane of post-synaptic dendritic spines. (C)
Phospholipids are the most abundant components of neuronal
membranes. (D) Dynamic phospholipid remodeling enables the rapid
alterations in membrane form and function required for synaptic
transmission while maintaining critical lipid composition essential for
synaptic structural integrity. The Land’s cycle is depicted. Hydrolysis of
the sn-2 arachidonyl chain of a 1-O-ether-linked choline-containing
glycerophospholipid by cPLA2 releases AA (20:4). The residual lyso-PAF
backbone can be remodeled by LPCAT1 at the plasma membrane into
the powerful PAF family of neuromodulators or reconstructed back into
a 1-O-alkyl-linked structural lipid depending upon whether an acetyl
group or a long chain fatty acid, primed by the actions of acyl-Co
synthetase, is used as a substrate. In turn, the sn-2 acetyl group
released by PAF-AH during conversion of PAFs back to lyso-PAFs can
be passed to an ester-linked lysophosphatidylcholine, a sphingolipid, or
another ether-linked lyso-PAF with either the same or different sn-1
chains. PAF-AH 1b does not have transferase activity; PAFAH II does.
This single pathway alone can generate a plethora of different
phospholipids through the simple exchange of constituent hydrocarbon
chains. Abbreviations: AA, arachidonic acid; cPLA2, cytoplasmic PLA2;
CoA, coenzyme A; LPCAT1, lysophosphatidylcholine acyltransferase 1;
lyso-PAF, lyso-platelet activating factor or 1-O-alkyl
lysoglycerophosphocholine; PAF, platelet activating factor or
1-O-alkyl-2-acetyl-glycerophosphocholine; PAF-AH, PAF-acetylhydrolase.
species that vary by only one double bond, a single methylene
group, or carbon chain linkage can now be quantified directly
in synaptic preparations. Further, new high-resolution optical
single molecule tracking approaches, notably fluorescence cor-
relation spectroscopy (FCS) coupled with the stimulated emis-
sion depletion fluorescence nanoscopy (STED) and fluorescence
lifetime imaging microscopy (FLIM), are facilitating, again for
the first time, the study of functional interactions specific to
lipid microdomains directly in living cells (Eggeling et al., 2009;
Kusumi et al., 2010; Sahl et al., 2010; Mueller et al., 2013). Basic
unitary conceptions are being challenged. Diacylglycerol (DAG),
commonly conceived by cell biologists as a single lipid second
messenger, is now recognized to be a family of over 50 struc-
turally distinct isoforms (Callender et al., 2007) each controlling
different cellular processes (Deacon et al., 2002).
EXPLORING A “LIPID-CENTRIC” VIEW OF SYNAPTIC
FUNCTION AND DYSFUNCTION IN AD
CONVERSION FROM A PRE-SYMPTOMATIC TO A SYMPTOMATIC
STATE IN AD REQUIRES MULTIPLE METABOLIC DISRUPTIONS
Two central pathologies define AD: (1) intraneuronal accumula-
tion of neurofibrillary tangles composed of hyperphosphorylated
tau and (2) aberrant processing of the amyloid precursor pro-
tein (APP) to smaller, toxic amyloid β (Aβ) fragments. The
most damaging is Aβ42. Accumulation is gradual with assem-
bly of soluble Aβ42 oligomers impairing synaptic function and
signaling neuronal loss (Cleary et al., 2005; Palop and Mucke,
2010; Benilova et al., 2012). The “amyloid cascade hypothesis”
defines these events as the root cause of AD (Hardy and Selkoe,
2002; Palop and Mucke, 2010; Benilova et al., 2012). Yet new
data suggests that these driving Aβ and tau pathologies likely
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FIGURE 2 | Synaptic phospholipids (and cholesterol). (A) Structural
membrane phospholipids are derivatives of sn-glycero-3-phosphoric acid
with a 1-O-acyl, a 1-O-alkyl (ether-linked plasmanyl), or a 1-O-alkyl-1′ -enyl
(vinyl ether-linked plasmenyl) carbon chain, a long-chain fatty acid
esterified to the sn-2 position, and a polar headgroup composed of a
nitrogenous base, a glycerol, or an inositol unit modifying phosphoric
acid at the sn-3 position. The polar head group defines different
phospholipid classes with 1-O-acyl linked PS, phosphatidylserine; PA,
phosphatidic acid; PI, phosphatidylinositol; PE, phosphatidylethanolamine;
and PC, phosphatidylcholine predominant in neuronal plasma
membranes. The free diffusion of these species through the lipid
bilayer is, in part, influenced by cholesterol, a sterol defined by a four
fused-ring core and an alkyl side-chain that preferentially solvates with
some but not all sn-1 and sn-2 phospholipid side chains. (B)
Phospholipids can be hydrolyzed by different families of PLAs. Cleavage
sites are depicted using PC(16:0/16:0) as the target substrate.
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represent only two of multiple determinants required for AD
conversion. This refinement is based on evidence that Aβ42 accu-
mulation (at AD load levels) can be detected in both cognitively
“normal” elderly and humanized mouse models with little learn-
ing and memory impairment (Snowdon, 2003; Zahs and Ashe,
2010). These observations have prompted a “re-imagining” of
the amyloid hypothesis (Herrup, 2010; Kuller and Lopez, 2011;
Nelson et al., 2011). Here, the amyloid deposition cycle, aggra-
vated by chronic neuroinflammation, triggers a critical “change
in state” (Herrup, 2010). This “change of state” is envisioned as a
convergence of metabolic disruptions resulting in “a new ‘nor-
mal’ biology primed toward neurodegeneration and dementia”
(Herrup, 2010).
PATHOLOGICAL MEMBRANE REMODELING MAY REPRESENT A
CRITICAL METABOLIC DISRUPTION REQUIRED FOR AD CONVERSION
Our overarching hypothesis is that multiple aberrations in
phospholipid metabolism are required for transition from pre-
symptomatic to symptomatic AD. Here, we seek to identify some
of these additional critical disruptions by mining existing neu-
rolipidomic datasets. Previous work has correlated the extent
of membrane phosphocholine (PC) and phosphoethanolamine
(PE) breakdown with severity of dementia and psychosis in
AD patients (Klein, 2000; Sweet et al., 2002). Moreover, soluble
oligomeric Aβ42 neurotoxicity is signaled, in part, by enhanced
metabolism of ether linked structural phospholipids (Sanchez-
Mejia et al., 2008; Ryan et al., 2009). Targeting upstream remod-
eling or downstream signaling of key metabolites can protect
human and murine neurons from Aβ42 in vitro and improve
behavioral indices of learning and memory in vivo (Kriem et al.,
2005; Sanchez-Mejia et al., 2008; Ryan et al., 2009). There is
also compelling evidence to indicate that the fatty acid sub-
strates available for phospholipid biosynthesis are altered over the
course of AD (Table S5). For example, using an unbiased neu-
rolipidomics approach, non-esterfied monounsaturated fatty acid
(MUFA) levels have been shown to increase in AD brain whereas
polyunsaturated (PUFA) levels generally decrease (Lukiw, 2009;
Astarita et al., 2010, 2011). These changes are attributed to
increased expression of three of the rate-limiting enzymes in
MUFA biosynthesis, stearoyl-CoA desaturase-1 (SCD-1) SCD-
5a and SCD-5b (Astarita et al., 2011). Enhanced activity is
thought to compensate for decreasing bioavailability of PUFA
substrates highlighting the molecular interdependency of lipid
metabolic defects that occur over the course of AD (Astarita et al.,
2011).
These disruptions may confer AD risk. Recent genome wide
association studies (GWAS) have identified variants in sortilin-
related receptor (Rogaeva et al., 2007), clusterin (Harold et al.,
2009; Lambert et al., 2009; Jun et al., 2010), bridging integrator
1 (Seshadri et al., 2010), ATP-binding cassette sub-family A
member 7 (Hollingworth et al., 2006), and phosphatidylinosi-
tol binding clathrin assembly protein (Harold et al., 2009; Jun
et al., 2010) genes as AD risk factors. Clearly, these genes
do not act through the same biochemical pathways yet each
shares in common a regulation of one or more aspects of neu-
ral phospholipid (and in some cases cholesterol) metabolism
with the canonical ApoE risk allele (Strittmatter et al., 1993).
Excitingly, there is also evidence that, once aberrant patterns
in phospholipid metabolism are identified, intervention may be
possible. Enhancing apolipoprotein E (ApoE)-dependent traf-
ficking of PUFAs from neurons to glia in APP/presenilin 1
(PS1) transgenic mice changes the phospholipid composition
of synaptosomes, increases Aβ42 clearance,and reverses learning
and memory impairment (Igbavboa et al., 2002; Cramer et al.,
2012). Conversely, inhibition or genetic ablation of phospho-
lipase D2 (PLD2) (Figure 2B), the group IV isoform of PLA2
(cPLA2) (Figure 2B), or synaptojamin, the primary phospho-
inositide PI(4,5)P2 phosphatase also confers synaptic protection,
reduces Aβ42 biosynthesis, and rescues memory deficits in APP
transgenics (Berman et al., 2008; Sanchez-Mejia et al., 2008;
Oliveira et al., 2010).
INTERPRETING SYNAPTIC GLYCEROPHOSPHOLIPIDOME
DATASETS
We used a post-hoc neurolipidomics approach to identify poten-
tial phospholipid determinants of AD cognitive impairment.
We first collated the findings of 29 published neurolipidomic
datasets generated using multiple methodologies, technologies
and human and murine samples (Tables S1–S4). If not explicitly
identified by the studies’ authors, we used the online bioin-
formatics tool VaLid to predict sn-1 and sn-2 carbon chain
stereospecificity (Blanchard et al., 2013). Results were combined,
heat-mapped, andmined for underlying patterns (Figure 3). This
analysis required that we set aside two of fundamental assump-
tions commonly applied to the interpretation of genomic and
proteomic datasets. First, we postulated that critical composi-
tions of synaptic lipids are likely not the ones altered early
in disease etiology but rather the species that exhibit a catas-
trophic depletion in late-stage disease. Unlike mRNA and protein,
individual phospholipids do not have their own synaptic half-
lives and cannot be tracked as single entities from biogenesis to
catabolism. Rather, following linkage determination in the endo-
plasmic reticulum and transport to synaptosomal membranes,
their defining sn-1 and sn-2 carbon chains (depending on link-
age to the phosphoglyceride backbone) and, to some extent, their
polar head groups are passed between species. Each of the free
fatty acids released by PLA1 or PLA2 hydrolysis (Figure 2B) has
its own synaptic half-life, ranging from 10 days for palmitic
acid (16:0) to 60 days for AA (20:4) (Ando et al., 2002). This
metabolic consubstantiality, wherein critical chemical composi-
tions are maintained through dynamic remodeling of multiple
species, enables the rapid changes in membrane curvature (and
fusion) required for neurotransmission while ensuring synaptic
structural integrity (Figures 4A–F). We argue that any quantifi-
able shift in these critical compositions likely indicates that a
catastrophic “change in state” has already occurred (i.e., evidence
of a membrane biology now “primed toward neurodegeneration
and dementia”). Second, we postulated that variations between
datasets in the composition of smaller glycerophospholipid inter-
mediates (i.e., the lysophospholipids, free fatty acids, and their
downstream metabolites) (Figure 1C) are not “noise” but likely
(1) snapshots of the structural species being actively mobi-
lized to maintain critical structural membrane compositions at
time of extraction and (2) identify the neuroactive phospholipid
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FIGURE 3 | The phospholipid landscape is altered in AD and mouse
models of AD or AD risk. (A) PE, (B) PC, (C) PS, (D) PI. Heat map display of
significant interactions (p < 0.05) statistically validated by the authors of the
following datasets: #1 (Takamori et al., 2006), #2–3 (Axelsen and Murphy,
2010), #4 (Brand et al., 2010), #5 (Igbavboa et al., 2002), #6–9 (Han et al.,
2001), #10–15 (Chan et al., 2012), #16–23 (Han et al., 2001), #24 (Mutka et al.,
2010), #25 (Sharman et al., 2010); #26 (Lohmann et al., 2010), #27–28 (Ryan
et al., 2009), #29 (Eberlin et al., 2010). The color scheme reflects statistical
changes in ApoE−/−, ApoE ε2, ε3, ε4 humanized knock-in (KI), cathepsinD
(Ctsd)−/− , APPSw transgenic, PS1 transgenic, PS1/APPSw double
transgenic, TgCRND8 transgenic mice, and post-mortem human AD brain
tissue relative to cognate controls as published. Where comparisons were
not made with disease or experimental conditions, color (green) simply
reflects detection in datasets. Where published datasets identified lipids by
total number of carbons and degree of unsaturation, assignment of sn-1 and
sn-2 chains in this study was performed as indicated in Tables S1–S4
(footnote#1). Tissue abbreviations: Cx, Cortex; Crb, cerebellum; ECx,
Entorhinal Cortex; FCx, Frontal Cortex/Prefrontal Cortex; Hip, Hippocampus;
PCx, Parietal Cortex; SPM, Synaptosomal membranes; SV, Synaptic Vesicle.
All other conditions are as described in Tables S1–S4.
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FIGURE 4 | Synaptic microdomains exhibit different critical
structural phospholipid compositions that are remodeled over the
course of neurotransmission. (A) In a simplified membrane-centric
model of excitatory neurotransmission, neurotransmitter released into
the synaptic cleft from vesicles by the pre-synaptic neuron, diffuses
across the intersynaptic space, to activate integral membrane
receptors present along dendritic spine microdomains. In the
post-synaptic neuron, receptors (and other necessary signaling
components) can be shuttled between (B) peri- and (D) post-synaptic
densities in (C) lipid rafts. An incoming axon potential at the axon
terminal can trigger the fusion of (F) synaptic vesicles along the
active zone within (E) pre-synaptic densities and the release of
neurotransmitter. Each domain is defined by a distinct profile of
constituent PC (red), PS (yellow), PE (blue) and PI (green) with
critical compositions required for structural integrity maintained
constant by this dynamic remodeling.
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signaling molecules that transiently accumulate in different dis-
ease states. We argue that these changes will emerge earlier
than catastrophic alterations in overall structural phospholipid
composition. Taken together, we maintain that the interpreta-
tion of lipidomic datasets depends less upon a determination
of absolute phospholipid levels (which will vary considerably
from laboratory to laboratory and methodology to methodol-
ogy) than upon identification of the patterns in lipid compo-
sition that are altered over the course of disease progression
(Brown and Murphy, 2009). Here, we present three such pat-
terns in membrane metabolism identified through analysis of
29 independent datasets predicted to signal synaptic dysfunction
in AD.
PATTERN 1: EVIDENCE FOR SYNAPTIC POISONING: A
PRIMARY ROLE FOR ETHER-LINKED PHOSPHOLIPIDS IN
MEDIATING AD VESICULAR DEPLETION
SYNAPTIC MICRODOMAINS EXHIBIT DIFFERENT PHOSPHOLIPID
PROFILES
Enrichment in PC, PE, PI, PS, specifically isoforms with
(16:0) and (18:1) carbon chains at both their sn-1 and sn-
2 positions, is detected in synaptosomal membranes pre-
pared from healthy mouse, rat, and human brain (Tables
S1–S4) 2. Given the dietary abundance of palmitic acid and
oleic acid, this pattern is, of course, expected. Yet there is
an intriguing molecular specificity that distinguishes differ-
ent synaptic microdomains (Figure 4A). In healthy murine
tissue, the relative abundance of PCs and 1-O-alkyl-PC iso-
forms (16:0/18:1) and (18:0/18:1) are higher in pre- and post-
synaptic densities relative to lipid raft domains (Igbavboa et al.,
2002; Martin et al., 2010) (Figures 4C–E). In synaptic vesi-
cles, PC(16:0/18:1)3 and, presumably PC(O-16:0/18:1), predom-
inate over PC(18:0/18:1) and PC(O-18:0/18:1) (Takamori et al.,
2006) (Figure 4F). Vesicular membranes (and synaptic lipid
rafts) are further defined by enrichment in diacyl-PCs with
fully saturated palmitic acid carbon chains [i.e., PC(16:0/16:0)]
but only a small percentage of the more elastic PS (and PI)
(16:0/16:0) species compared to non-raft domains (Takamori
et al., 2006; Martin et al., 2010). Finally, fewer acyl-linked PC,
PE, and PS species with docosahexaenoic acid (DHA, 22:6)
at their sn-2 positions are found in isolated synaptic vesicles
relative to other synaptosomal microdomains and brain tissue
(Williams et al., 2000; Han et al., 2001; Takamori et al., 2006;
Wurtman et al., 2009; Axelsen and Murphy, 2010; Martin et al.,
2010).
2These patterns are based on a comparison of the relative abundance within
control datasets (wild-type mouse or normal elderly). References and com-
parative summary of relative phospholipid abundance within these datasets
are presented in Tables S1–S5.
3We use the LIPID MAPS classification system nomenclature (Fahy et al.,
2011). PC(16:0/18:1), for example, defines a lipid species with a phospho-
choline polar head group (PC), an ester linkage at the sn-1 position, carbon
chains at the sn-1 and sn-2 positions of 16 and 18 carbons, respectively, of
which the sn-1 chain is fully saturated (referred to as :0), whereas the sn−2
has one double bond (referred to as :1). Alkyl (O-) and alkenyl (P-) linkages
are indicated before the appropriate sn chain when discussing PlsEtns, PAFs,
or PAF precursors.
PC(16:0/16:0), PC(O-16:0/20:4), PC(O-16:0/22:6), PE(P-18:0/20:4), AND
PE(P-16:0/22:6) REPRESENT CRITICAL VESICULAR PHOSPHOLIPID
COMPOSITIONS
These restrictions are surprisingly linkage- and position-specific.
Unlike acyl-linked PCs and PEs, 1-O-alkyl-linked species (PAF
precursors) and ethanolamine-containing 1-P-alkenyl plasmalo-
gens (PlsEtns) in brain frequently exhibit either AA (20:4)
or DHA (22:6) in addition to oleic acid (18:1) at their sn-2
positions (Igbavboa et al., 2002; Takamori et al., 2006; Bruno
et al., 2007; Martin et al., 2010). Moreover, in PAF precur-
sors, fully saturated sn-1 ether-linked (16:0) chains dominate
[PC(O-16:0/20:4) or PC(O-16:0/22:6)]. By contrast, PlsEtns dis-
play a positional preference for either vinyl ether-linked stearic
acid (18:0) at their sn-1 and acyl-linked AA (20:4) at their sn-
2 positions4 or vinyl ether-linked (16:0) chains at their sn-1 and
acyl-linked DHA (22:6) at their sn-2 positions5 (Han et al., 2001;
Igbavboa et al., 2002; Takamori et al., 2006; Ryan et al., 2009;
Axelsen and Murphy, 2010; Brand et al., 2010; Eberlin et al.,
2010; Lohmann et al., 2010; Sharman et al., 2010). Together,
these profiles suggest a higher requirement for 16 carbon chains
at both the sn-1 and sn-2 positions, a predominance of diacyl
PC(16:0/16:0), an enrichment of PC(O-16:0/20:4) and PC(O-
16:0/22:6) PAF precursors, and an abundance of the PlsEtns
PE(P-18:0/20:4) and PE(P-16:0/22:6) in vesicular membranes of
“normal” synapses.
MEMBRANE REMODELING REQUIRED FOR NEUROTRANSMITTER
RELEASE IS REGULATED, IN PART, BY THE SUBSTRATE SPECIFICITIES
OF SYNAPTIC PHOSPHOLIPASES
Vesicle diameter, measured by cryo-electron microscopy, ranges
between 30 and 60 nm, with an average diameter of 42 nm
(Takamori et al., 2006; Castorph et al., 2010). A single phospho-
lipid occupies a space of ∼65 Å2 (0.65 nm2) (Takamori et al.,
2006; Castorph et al., 2010). With phospholipid composition cal-
culated as 50–75% of the total lipid content, each 42 nm diameter
vesicle is estimated to contain around 7000 individual species
(McMahon and Gallop, 2005; Takamori et al., 2006). Structure,
in part, dictates topography. The extreme curvature of vesic-
ular membranes places more phospholipids in the outer and
fewer in the inner leaflet to balance the spatially larger exte-
rior positive curvature with the spatially smaller interior negative
curvature (McMahon and Gallop, 2005; Takamori et al., 2006)
(Figure 4F). Phospholipid identity within these leaflets must
also reconcile the need to stabilize vesicular structure with the
requirement to rapidly reverse membrane curvature and fuse
with the plasmamembrane on demand (Figure 4F). In a protein-
centric view, these dynamics are conceptually better suited to
pliant fusogenic phospholipids whose physicochemical natures
are “released” once the structural constraints enforced by inte-
gral membrane proteins are relaxed (McMahon and Gallop,
2005). Such a model makes the predominance of saturated dia-
cyl PC(16:0/16:0) lipids in isolated synaptic vesicles somewhat
4PE(P-18:0/20:4) or 1-(1Z-octadecenyl)-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-
sn-glycero-3-phosphoethanolamine.
5PE(P-16:0/22:6) or 1-(1Z-hexadecenyl)-2-(4Z,7Z,10Z,13Z, 16Z,19Z-docos
ahexaenoyl)-sn -glycero-3-phosphoethanolamine.
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surprising (Takamori et al., 2006). Reconstitution studies indi-
cate that the cylindrical geometries of dipalmitoyl-PCs are more
suited to the generation of planar membranes or, in presence
of water, to the formation of vesicles with a longer-lived sta-
ble structure under negative tension (McMahon and Gallop,
2005; Shinoda et al., 2010). The enrichment of PC(16:0/16:0)
would therefore be expected to render synaptic vesicles more
fusion-resistant yet these neurolipidomic profiles are supported
by small angle neutron scattering analysis detecting cylindri-
cally shaped lipids within mini-microdomains of ∼15 nm in
length along the perimeter of reconstituted vesicles (Vogtt et al.,
2010).
Form reveals function when placed in context with the dynam-
ics of synaptic phospholipase substrate specificities (Figure 4A).
Secretary phospholipase A2 isoforms (sPLA2, Group IIA and pos-
sibly Group V) and PlsEtn-selective phospholipase A2 (PlsEtn-
PLA2) are preferentially activated at sites of vesicular fusion
(Kolko et al., 2003; Wei et al., 2003; Takamori et al., 2006).
Group IIA sPLA2, released at the synapse, displays a low affin-
ity for ester-linked acyl-PCs and a high affinity for ether-linked
1-O-alkyl-PCs (Pruzanski et al., 1998; Boyanovsky and Webb,
2009). Intracellular calcium-independent PlsEtn-PLA2 preferen-
tially hydrolyzes DHA (22:6) from PlsEtns species (Ramadan
et al., 2010). Hydrolysis of the outer leaflets of vesicular mem-
branes (by intracellular PlsEtn-PLA2) and of pre-synaptic den-
sities (by sPLA2,), releasing AA (20:4) from PC(O-16:0/20:4)
and DHA (22:6) from PE(P-16:0/22:6), would indeed generate
highly fusogenic wedge-shaped lyso-PAFs and lyso-plasmalogens
without impacting on neighboring diacyl-PCs. The geome-
tries of lyso-PAF PC(O-16:0/0:0), lyso-PlsEtn PE(P-16:0/0:0),
and lyso-PlsEtn PE(P-18:0/0:0) are predicted to favor the rever-
sal from negative to positive curvature required for the fusion
pore formation (Piomelli et al., 2007; Shin et al., 2010)
(Figure 4F). These lyso-lipids have also been shown to regu-
late soluble N-ethylmaleimide-sensitive factor attachment recep-
tor (SNARE) protein complexes embedded both in vesicu-
lar (v-SNARE) and pre-synaptic target (t-SNARE) membranes.
SNARE complexes direct vesicular fusion with activities mod-
ulated by their phospholipid binding partners. Association
with acyl-linked lysophospholipids promotes the formation of
larger of t-/v-SNARE protein complexes slowing down vesi-
cle fusion while association with lyso-PlsEtns enhances the
formation of smaller complexes speeding up fusion (Glaser
and Gross, 1994). Moreover, the free DHA (22:6) and AA
(20:4), released from the sn-2 position of ether-linked struc-
tural membrane lipids by the actions of sPLA2 and PlsEtn-PLA2,
can themselves signal enhanced basal release of noradrenaline,
again apparently through converging feedback mechanisms
that activate SNAREs (Darios et al., 2010; Geraldine et al.,
2010).
ENHANCED HYDROLYSIS OF VESICULAR PAF PRECURSORS AND
MEMBRANE PLSETNS IS MECHANISTICALLY CONSISTENT WITH THE
HYPOTHESIS THAT INCREASED VESICULAR RELEASE PRECIPITATES
VESICULAR DEPLETION OVER THE COURSE OF AD
MS profiling of post-mortem AD brain as well as tissue and
synaptosomes isolated from transgenic models of AD and AD
genetic risk factors provide strong evidence that this pattern is
disrupted over the course of AD (Figures 3A–D). Specifically,
a depletion in DHA (22:6), an increase in free AA (20:4), and
an accumulation of ether-linked fusogenic lyso-phospholipids
defined by (16:0) carbons at their sn-1 position are consis-
tently detected across datasets (Sanchez-Mejia et al., 2008; Ryan
et al., 2009; Astarita et al., 2010, 2011). This particular pat-
tern is remarkably similar to the acute changes in free fatty
acids and phospholipid profiles observed following toxin-induced
synaptic depletion in snake venom poisoning. Certain snake ven-
oms act to stimulate vesicular fusion, partially by enhancing
phospholipase-dependent structural membrane lipid hydrolysis,
while simultaneously inhibiting the remodeling of the ether and
vinyl-ether linked lyso-phospholipid metabolites required for the
subsequent reconstitution of vesicular membranes. The net effect
is vesicular depletion precipitating acute synaptic failure (Valentin
and Lambeau, 2000). This phenomenon can also be artifi-
cially induced simply by the addition of the lyso-phospholipids
at concentrations that inhibit their own remodeling (Rigoni
et al., 2005; Rossetto et al., 2006). The phospholipid profiles
detected in AD datasets mirror this pattern of synaptic poi-
soning (Figures 3A–D) albeit over a much longer time course.
Changes are consistent with the hypothesis that enhanced vesicu-
lar release in patients suffering from mild cognitive impairment
(MCI), precedes (and likely precipitates) the vesicular deple-
tion seen in moderate to late stage AD (DeKosky et al., 2002;
Truchot et al., 2007). Certainly, acute exposure of primary neu-
rons to Aβ oligomers enhances vesicular fusion and increases
the rate of neurotransmitter release while chronic exposure
depletes neurons of synaptic vesicles and impairs neurotransmis-
sion (Dante et al., 2008; Nimmrich and Ebert, 2009; Parodi et al.,
2010).
Enhanced hydrolysis of vesicular PAF precursors and mem-
brane PlsEtns may play a determinative role in mediating this
transition. In a series of unbiased lipidomic approaches, Aβ
oligomers were found to enhance the rate of 1-O-alkyl-linked
PC hydrolysis leading to an accumulation of AA (20:4) and lyso-
PAF (O-16:0) both in vitro and in vivo (Sanchez-Mejia et al.,
2008; Ryan et al., 2009). The activities of both PlsEtn-PLA2 and
sPLA2are elevated in AD brain relative to controls, as measured
directly in synaptosomes prepared from post-mortem tissue or
assayed in cerebrospinal fluid (Chalbot et al., 2009; Farooqui,
2010). Some ESI/MS profiles indicate that PE(P-16:0/18:1), PE(P-
18:1/20:4), PE(P-18:0/22:6), and PE(P-18:1/22:6), but not their
acyl-linked PE counterparts are selectively reduced in AD brain
(Han et al., 2001) (Figure 3A, Table S1). Interestingly, this link-
age specificity does not consistently extend to PlsEtns with (16:0)
carbons at the sn-1 chain and DHA (22:6) or AA (20:4) at
the sn-2 position (Han et al., 2001). Together, these variations
suggest that critical PE(P-16:0/22:6) and PE(P-16:0/20:4) com-
positions may be maintained for longer periods of time in AD
brain possibly by enhancing the compensatory remodeling of
other lipid subsets. These individual compensatory responses are
suggested by the variations detected between datasets of rela-
tive levels of other AA and DHA-containing structural lipids
(Figures 3A–D, Tables S1–S4). The reason for the sn-1 speci-
ficity is unclear although loss of ApoE, a risk factor associated
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with AD, has been shown to alter the traffic of polyunsaturated
lipids from astrocytes to neurons, biasing the composition of
long-chain fatty acids in synaptosome PCs toward fully satu-
rated (16:0) species in null-mutant mice (Igbavboa et al., 2002)
(Figure 3B, Table S2). Certainly, PC(16:0/16:0) species increase in
ApoE-deficient mice (Igbavboa et al., 2002) (Figure 3B, Table S2).
Furthermore, the calcium-independent PLA2γ (iPLA2γ) isoform,
capable of hydrolyzing both sn-1 and sn-2 fatty acid chains of dia-
cyl phospholipids and sn-2 chains of O-alkylacylphospholipids,
shows specificity for (16:0) carbon chains (Yan et al., 2005).
iPLA2 activity is downregulated in some AD patients and this
may also contribute to the enrichment in PC(16:0/16:0), PAF(O-
16:0/2:0), and lyso-PAF(O-16:0/0:0) detected in someMS datasets
(Talbot et al., 2000; Ryan et al., 2009) (Figure 3B, Table S2).
These responses would, in turn, be expected to render new vesi-
cles more fusion-resistant over time in the face of ongoing DHA
depletion.
REDUCTIONS IN PE(P-16:0/22:6) AND PE(P-16:0/20:4) CORRELATE WITH
SEVERITY OF AD COGNITIVE IMPAIRMENT
Not all profiles, however, detect sparing of PE(P-16:0/22:6)
and PE(P-16:0/20:4) in AD (Figure 3A, Table S1). In studies
where these species are reduced, loss correlates with clinical
dementia scores but, interestingly, not always with post-mortem
AD pathology (Han et al., 2001). Patients with less Aβ and
tau pathology but a greater reduction in PlsEtns are more
impaired than those with exacerbated primary pathology but
little change in PlsEtns profile (Han et al., 2001). Similarly,
enhanced turnover of structural PlsEtns and PCs, manifested
by an accumulation of smaller lyso-plasmalogens and choline-
containing metabolites detected by magnetic resonance spec-
troscopy, correlates with more severe cognitive impairment, dete-
rioration, and psychosis (Sweet et al., 2002). Together, these
data point to a primary impact of PlsEtn deficiency on synap-
tic function and highlight PE(P-16:0/22:6) and PE(P-16:0/20:4)
and to a lesser extent lyso-PAF PC(O-16:0/0:0) as critical phos-
pholipids species regulating vesicular fusion at the membrane
level.
PATTERN 2: BREAKDOWN OF THE SECONDMESSENGER
GLYCEROPHOSPHOLIPIDOME: ABERRANT PHOSPHOLIPID
SECOND MESSENGER SIGNALING CASCADES CAN
TRANSDUCE AD PATHOLOGY AND ENHANCE Aβ
BIOGENESIS
DEPLETIONS IN PI(16:0/20:4), PI(16:0/22:6), AND PI(18:0/22:6) LIKELY
ACCELERATE Aβ BIOGENESIS
Metabolism of structural membrane PIs and 1-O-alkyl PAF pre-
cursors generates powerful lipid second messengers. Differential
distribution of phosphorylated PI metabolites is required for
synergistically assembling and remodeling the SNARE com-
plexes providing a second means by which synaptic phospho-
lipids may directly regulate neurotransmission. PI(4,5)P2 and
PI(3,4,5)P3 are enriched in plasma membrane with 16:0/18:1,
18:0/20:4, and 18:0/22:6 isoforms predominating (Igbavboa
et al., 2002). PI(4)P is found more frequently in Golgi mem-
branes while PI(3)P and PI(3,5)P2 are enriched in endoso-
mal membranes (Lasiecka et al., 2009). In yeast, PI(3)P both
enhances the capacity of membrane-bound SNARES to drive
fusion in the absence of SNARE chaperones as well as syn-
ergistically activates SNARE chaperones to recruit Vam7p into
fusion-competent complexes. PI(3)P has also been shown to
be required for the subsequent SNARE complex disassem-
bly once fusion is complete and cargo released (Mima and
Wickner, 2009a,b). In neurons, this process further depends
upon interaction with PI(4,5)P2 found in highest concentra-
tions at pre-synaptic densities. Decreasing PI(4,5)P2 abolishes
the ability of the v-SNARE-regulator, synaptotagmin-1, to inter-
act with both the pre-synaptic membrane and t-SNARE pre-
complexes thereby preventing calcium-dependent release of neu-
rotransmitter from the pre-synaptic active zone (Lee et al.,
2010).
Again, these critical compositions are disrupted in AD
(Figure 3D, Table S4). Early studies detected a reduction in
overall PI content in the temporal cortex of AD patients post-
mortem (Stokes and Hawthorne, 1987). LC-ESI-MS analysis
of ApoE-deficient mice has identified a key molecular speci-
ficity in the depletion of PI(16:0/20:4), PI(16:0/22:6), and
PI(18:0/22:6) species at synaptic membranes coupled, in some
profiles, with an aberrant increase in PI(18:0/20:4) (Igbavboa
et al., 2002; Chan et al., 2012). These changes are not only
predicted to impair neurotransmitter release but also to enhance
γ-secretase activity, responsible for cleavage of APP to Aβ.
PI(3)P(16:0/16:0), PI(4)P(16:0/16:0), PI(3,4)P2(16:0/16:0),
PI(4,5)P2(16:0/16:0), and PI(3,4,5)P3(16:0/16:0), but not
PI(16:0/16:0), PI(5)P(16:0/16:0), or IP3 inhibit γ-secretase
activity in vitro (Osawa et al., 2008). Although carbon chain
specificity has yet to be assessed, it is reasonable to assume
that the depletion of PI(16:0/20:4) and PI(16:0/22:6), pre-
cipitated by loss of ApoE function, will also contribute to
accelerating the processing of synaptotoxic Aβ peptides by
γ-secretases.
PROGRESSIVE DEPLETION OF PI(4,5)P2 TRANSIENTLY INCREASES
VESICULAR FUSION AND CHRONICALLY IMPAIRS
NEUROTRANSMITTER RELEASE
Metabolic interdependency is, however, underlined by the fact
that the familial AD mutations in presenilin 1 and 2, in
turn, impair PI(4,5)P2 metabolism effectively reducing levels in
vesicular and pre-synaptic membranes (Landman et al., 2006).
Moreover, in experimental models of AD, PI(4,5)P2 is down-
regulated in response to synaptotoxic oligomeric Aβ42 (but not
monomeric or fibrillar configurations). This decrease is medi-
ated, in part, by increases at the pre-synaptic active zone in
the Ca2+dependent activation of PLC hydrolyzing PI(4,5)P2 to
DAG and IP3 as well as increased activity of synaptojanin 1,
the primary PI(4,5)P2 phosphatase present at neuronal synapses
(Berman et al., 2008). In axons, the hydrolysis of PI(4,5)P2
by synaptojanin 1, drives the inner leaflet to adopt a nega-
tive curvature that embraces trafficking vesicles during fusion
(Cremona et al., 1999). Such activity provides another lipid-
centric mechanism by which oligomeric Aβ42 acutely increases
vesicular fusion then chronically impairs neurotransmitter release
(Dante et al., 2008; Nimmrich and Ebert, 2009; Parodi et al.,
2010).
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INTRANEURONAL ACCUMULATION OF PC(O-16:0/2:0) AND AA DISRUPT
TAU PROCESSING AND SIGNAL NEURONAL LOSS
Aβ42 has also been shown to activate cPLA2 promoting its
calcium-dependent translocation to multiple subcellular mem-
branes (Lee et al., 2011). cPLA2 preferentially hydrolyzes AA
(20:4) from the sn-2 position of 1-O-alkyl-2-arachidonoyl- and
1-O-acyl-2-arachidonoyl-glycerophospholipids (Kita et al., 2006)
(Figure 1D). The alkyl-lysophospholipid backbone can then be
modified by LPCAT1 at the plasma membrane to either regener-
ate structural membrane lipids or produce 1-O-acetyl-linked PAF
second messengers (Shindou et al., 2007; Harayama et al., 2008)
(Figure 1D). LPCAT activity has also been shown to increase in
AD (Ross et al., 1998), notably in the posterior-temporal entorhi-
nal cortex, a region characterized by the earliest tau pathology
(Bierer et al., 1995). We have shown that in AD temporal cortex,
transgenic models of AD, and human neurons, the regeneration
of structural membrane lipids from this backbone is impaired
(Ryan et al., 2009). In the presence of Aβ42, LPCATs appear
preferentially to utilize acetyl-CoA over acyl-CoA converting lyso-
PAFs to PAFs and not back to O-alkylacylglycerophosphocholine
structural lipids (Ryan et al., 2009). Unbiased neurolipidomic
approaches have detected both a net increase in the release of free
AA (20:4) and elevations in intraneuronal lyso-PAF(O-16:0/0:0)
and PC(O-16:0/2:0) (PAF) in AD patients, two different trans-
genic models of AD, and neuronal cultures exposed to Aβ42
(Kriem et al., 2005; Sanchez-Mejia et al., 2008; Ryan et al.,
2009) (Figure 3B, Table S2). Acute intraneuronal accumulation
of PC(O-16:0/2:0) but not PAF species with other sn-1 car-
bon chains initiates an endoplasmic reticulum stress-dependent
signaling cascade culminating in the hyperphosphorylation of
tau on Alzheimer Disease-specific epitopes by cyclin-dependent
kinase 5 (Ryan et al., 2008, 2009). If concentrations remain ele-
vated, PC(O-16:0/2:0) signals a calpain-caspase cascade resulting
in neuronal death (Ryan et al., 2007, 2008, 2009). While genetic
ablation, knockdown, or pharmacological inhibition of cPLA2
activation completely attenuates Aβ42 neurotoxicity; blocking the
different metabolic arms of the AA (20:4) cascade or preventing
the accumulation of PC(O-16:0/2:0) PAF confers only partial pro-
tection suggesting that both the AA cascade and PC(O-16:0/2:0)
PAF pathways act synergistically to transduce Aβ42neurotoxicity
(Kriem et al., 2005; Firuzi et al., 2008; Sanchez-Mejia et al., 2008;
Ryan et al., 2009). Thus, structural membrane metabolism may
be more than a biomarker of dementia. Accumulation of specific
choline-containing phospholipid metabolites detected in vivo by
magnetic resonance spectroscopy (Klein, 2000; Sweet et al., 2002)
may contribute directly to signaling cognitive decline.
PATTERN 3: THE FRANKENSTEINIAN SYNAPSE: DENDRITIC
DEFORMATION AND DHA
LIPID RAFT MOVEMENT IS REGULATED BY DYNAMIC CHANGES IN
PERI- AND POST-SYNAPTIC PHOSPHOLIPID COMPOSITIONS
Finally, neurolipidomic profiling combined with high resolution
imaging approaches are also revealing a reorganization of post-
synaptic microdomains in ADmechanistically associated with the
dendritic spine deformation and dysfunction (Tackenberg et al.,
2009). Like pre-synaptic and vesicular membranes, dendritic
peri- and post-synaptic densities are enriched in PE and PlsEtn
isoforms (Figures 4B–F) but, as discussed above, with a func-
tional topography (Han et al., 2001; Igbavboa et al., 2002;
Takamori et al., 2006; Ryan et al., 2009; Axelsen and Murphy,
2010; Brand et al., 2010; Eberlin et al., 2010; Lohmann et al.,
2010; Sharman et al., 2010) (Figure 3A, Table S1). Application
of STED-FCS and single molecule optical tracking approaches
to the study of lipid dynamics in living cells further reveals
a remarkable territoriality to the free diffusion of structural
lipids through cell membranes suggesting that lipid composi-
tion may regulate the direction of lipid raft movement between
peri- and post-synaptic densities. Phospholipids appear to be lim-
ited in their free diffusion within membranes to subdomains of
∼20 nm in diameter (Eggeling et al., 2009; Sahl et al., 2010).
The speed at which membrane lipids patrol these territories
is cholesterol-assisted and backbone-specific. Sphingolipids, for
example, freely diffuse traversing a 3 nm membrane radius of
their territory within 3ms in the absence of cholesterol. When
cholesterol is present, they become trapped for up to 17ms in
these same regions. PE(16:0/16:0) pays little heed to cholesterol,
diffusing at rates of less than 4ms regardless of the presence
or absence of cholesterol (Sahl et al., 2010). Thus, the enrich-
ment of sphingolipids within cholesterol-rich lipid rafts is likely,
in part, ensured by their lethargy in the presence of cholesterol
while the presence of PEs (and PlsEtns) and alkylacylPCs at the
borders of lipid rafts may reflect a functional interaction with
cholesterol (Tables S1, S2). Here, isoform specificity comes into
play. Converging artificial membrane reconstitution studies using
2H NMR, nuclear Overhauser enhancement spectroscopy in 1H
magic angle spinning NMR, X-ray diffraction, and solid-state
2H NMR strongly suggest that cholesterol exhibits an aversion
for DHA and the unsaturated 1-O-alkyl chains of PAF precursor
lipids. Rather, cholesterol favors solvation with saturated (16:0)
or (18:0) chains (Brzustowicz et al., 1999, 2002a,b; Shaikh et al.,
2002; Pitman et al., 2004; Kusumi et al., 2010). These properties
posit a “slip-stream” model of raft movement. Sphingolipid-
rich microdomains likely move away from membrane regions
where their cholesterol constituents come into apposition with
the sn-2 DHA (22:6) chains of PE(16:0/22:6), PE(18:0/22:6),
PE(P-16:0/22:6), PE(P-18:0/22:6), and PS(18:0/22:6) or the hex-
adecyl and octadecyl alcohols of 1-O-linked PEs and PCs. They
likely move toward regions with companionable PC(16:0/18:1),
PS(16:0/18:1), and PE(16:0/18:1) (Tables S1–S3). One could also
envisage that the radial rotation of PE(16:0/22:6), for example,
pirouetting to solvate its 16:0 sn-1 hydrocarbon with cholesterol
could also create eddies and currents in dendritic microdomains
promoting directional raft movement through the bilayer
schematically presented at a single time point in Figure 5A.
COMPOSITIONAL SPECIFICITY IN DHA DEPLETION
MORPHOLOGICALLY DEFORMS DENDRITIC SPINES
Disruptions in these patterns are associated with both impair-
ment of lateral trafficking of receptors along dendriticmembranes
and morphological deformation of peri- and post-synaptic
densities in AD and animal models of AD (Figure 5B). It is
well-established that DHA (22:6) concentrations decrease in
AD brain, liver, and AD risk models (Farooqui et al., 2007;
Lukiw and Bazan, 2008; Pomponi and Bria, 2008; Pauwels et al.,
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FIGURE 5 | The Frankensteinian dendritic spine. (A) Schematic model of a
healthy spine. Species within the outer leaflet of post-synaptic densities are
more consistently defined by either saturated (16:0) or (18:0) carbon chains at
their sn-1 and DHA (22:6) at their sn-2 positions. PS(18:0/22:6) is more
frequently found within the inner leaflet. The lipid raft domains that float freely
through these densities and shuttle receptors and their effectors to and from
peri- and post-synaptic compartments are depleted of phospholipids relative to
non-raft domains yet enriched in cholesterol and sphingolipid isoforms. Their
residual phospholipid constituents favor saturated palmitic acid (16:0) and
stearic acid (18:0) and mono-unsaturated palmitoleic acid (16:1) and eicosenoic
(20:1) fatty acyl chains with PC head-groups predominating. (22:6)–containing
PEs and PlsEtns in synaptosomal membranes are found in regions of greatest
curvature and highest cholesterol content. This pattern suggests an
accumulation of PE(16:0/22:6), PE(18:0/22:6), PlsEtn(16:0/22:6),
PlsEtn(18:0/22:6) in the outer leaflet and elastic PS(18:0/22:6) in the inner
leaflet of post-synaptic densities. (B) The Frankensteinian AD spine. Aberrant
changes in lipid composition in the face of ongoing DHA depletion are
fundamentally change the post-synaptic profile. The potential impact of these
changes is presented in this schematic likely manifesting as a thinner dendritic
spine and with bulkier lipid rafts more susceptible to drift from pre-synaptic
densities into peri-synaptic domains given the (1) loss of PI and PI metabolites
from the inner leaflet, (2) progressive reduction in PE(16:0/22:6), PE(18:0/22:6),
PlsEtn(16:0/22:6), PlsEtn(18:0/22:6), and PS(18:0/22:6) throughout the bilayer,
and (3) aberrant remodeling and accumulation of PS(22:6/22:6) at the outer
leaflet demonstrated by neurolipidomic approaches. Within lipid rafts, the
further accumulation of saturated (16:0/16:0) side chains in choline-containing
lipids at the expense of monounsaturated chains is predicted to alter receptor
conformation with the loss of enforced negative curvature by mono and
polyunsaturated side chains in direct apposition [compare the configuration of
an idealized receptor binding site in (A) and (B)].
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2009; Astarita et al., 2010; Seshadri et al., 2010). Depletion
occurs again with remarkable isoform specificity. For exam-
ple, in synaptic membranes isolated from ApoE-deficient mice,
DHA-containing PS(18:0/22:6), PS(22:5/22:6), PC(18:1/22:6),
PI(16:0/22:6), and PI(18:0/22:6) species are reduced yet di-
polyunsaturated PS(22:6/22:6), PE(22:6/22:6), and PC(22:6/22:6)
species are enhanced relative to wild-types (Igbavboa et al., 2002)
(Figures 3A–C, Tables S1–S3). Further, in some MCI patients,
most ADpatients, and APP/PS-1 double transgenic mice, a reduc-
tion in flippase activity, responsible for translocating PS isoforms
within synaptic bilayers is reduced resulting in the accumula-
tion of PS at the outer leaflet of synaptosomal membranes (Bader
Lange et al., 2008, 2010). Because phospholipid length is directly
proportional to the number of carbon atoms yet inversely pro-
portional to the number of double bonds in each carbon chain
(Shaikh et al., 2009), the combinations of the regional enrich-
ment of PS(22:6/22:6), PE(22:6/22:6), and PC(22:6/22:6), the
depletion of other DHA-containing isoforms throughout post-
synaptic membranes, and the reduction of PS(18:0:/22:6) at the
inner leaflet would most likely thin regions of peri- and post-
synaptic densities while making integral lipid rafts more bulky
and less mobile (Figure 5B). These changes are predicted to
impair synaptic transmission. This neurolipidomic interpreta-
tion inferred from phospholipid composition is consistent with
previous hypotheses based on observations of physicochemi-
cal lipid properties (Piomelli et al., 2007; Pomponi and Bria,
2008). Certainly transgenic mice ectopically expressing human
tau exhibit thinner apical and basal dendritic spines associated
with a reduction in synaptic strength (Dickstein et al., 2010).
This pattern is also consistent with the morphological deforma-
tion, dystrophy, and ultimate loss of dendritic spines detected by
Golgi impregnation and electron microscopy of post-mortem AD
cortex (Baloyannis et al., 2007).
CONVERGING METABOLIC DISRUPTIONS IN PI, PE, PLSETNS
METABOLISM AND DHA BIOAVAILABILITY IS PREDICTED TO IMPAIR
RECEPTOR TRAFFICKING BETWEEN PERI- AND POST-SYNAPTIC
DENSITIES
DHA (22:6) depletion may also directly impact upon receptor
density and chemical reception at post-synaptic densities. Aβ
oligomers contribute to the impairment of synaptic transmis-
sion, in part, by disrupting the endocytosis and trafficking of
AMPA and NMDA receptors at dendritic spines (Durakoglugil
et al., 2009; Rui et al., 2010). In vitro, receptors are both rapidly
removed from post-synaptic densities and fail to re-insert dur-
ing synaptic potentiation following exposure of hippocampal
neurons to oligomeric Aβ (Rui et al., 2010). Although underly-
ing mechanisms have only begun to be elucidated, the reduc-
tion in PI metabolites and the depletion of DHA from PE
and PlsEtns isoforms detected across multiple neurolipidomic
datasets are implicated (Figures 3A,D, Tables S1, S4). In den-
drites, PI(3,4,5)P3, generated, in large part, through the actions
of class I phosphatidylinositol-3-kinases (PI3Ks), is required to
maintain AMPA receptors at post-synaptic densities (Arendt
et al., 2010). Inhibition of PI(3,4,5)P3 synthesis enhances AMPA
receptor mobility such that they drift from post- to peri-synaptic
sites (Arendt et al., 2010). This biology is likely reinforced by the
depletion of PI precursors, notably PI(16:0/20:4), PI(18:0/20:4),
PI(16:0/22:6), and PI(18:0/22:6) observed in ApoE-deficient and
AD transgenic mice (Igbavboa et al., 2002; Chan et al., 2012).
Within this Frankensteinian synapse—a term we have coined to
describe the result of this catastrophic transformation brought
about by aberrant changes in lipid composition—rafts would be
no longer “corralled” within post-synaptic densities but rather
would be free to diffuse to and from peri-synaptic regions
(Figure 5B). In support of this hypothesis, post-synaptic den-
sity protein 95 (PSD-95), a specialized scaffolding protein that
complexes receptors with cytoskeletal elements at the synapse,
is reduced at post-synaptic densities when cellular membranes
are experimentally depleted of DHA yet enriched following DHA
supplementation (Wurtman et al., 2009; Langelier et al., 2010).
Further, recent evidence that ongoing systemic DHA depletion
(Astarita et al., 2010) is compensated for by increased MUFA
biosynthesis (Astarita et al., 2011) suggest that these critical
metabolic disruptions are likely mutually negatively reinforcing
thereby playing a determinative role in precipitating the “critical
change of state” required for AD conversion.
CONCLUSIONS: WHAT DO CHANGES IN PHOSPHOLIPID
COMPOSITION TELL US ABOUT AD SYNAPTIC
DYSFUNCTION?
Advances in genomics have identified genetic determinants of
neurodegenerative disease. Direct biochemical investigations have
elucidated multiple signaling pathways altered by these genetic
determinants leading to cognitive deterioration (Kim and Tsai,
2009; Nimmrich and Ebert, 2009). The combination of genomics
with proteomics is being used to map the temporal changes in
gene and protein expression that occur during transition from
pre-symptomatic to symptomatic disease states. We argue that
the next major advance in rational therapeutic design will come
from tying the dynamics of the susceptible cellular metabolome
into these genomic and proteomic maps of disease. The emerg-
ing field of neurolipidomics is identifying patterns of membrane
disruption predicted to confer AD risk. In this analysis, three
overarching metabolic disturbances were detected by post-hoc
analysis of 29 independent datasets. These impairments include
an increase in the hydrolysis of PAF precursors and membrane
PlsEtns coupled with a failure to regenerate these relatively rare
alkyl-acyl and alkenyl-acyl structural phospholipid compositions.
Initially, pathological disruptions appear to affect specific phos-
pholipids defined by carbon chain length, linkages, and degree
of unsaturation. For example, decreases in PE(P-16:0/22:6) and
PE(P-16:0/20:40 correlate with disease severity. Moreover, accu-
mulation of specific bioactive PAF and PlsEtns metabolites [i.e.,
PC(O-16:0/2:0) and PE(P-16:0/0:0)] are implicated in accelerat-
ing tau pathology, enhancing vesicular release leading to vesic-
ular depletion, and signaling neuronal loss. Further depletion
of PI(16:0/20:4), PI(16:0/22:6), and PI(18:0/22:6) likely accel-
erates Aβ42 biogenesis at the synapse although this hypothesis
still requires direct validation. Finally, converging disruptions in
PAF precursor and membrane PlsEtn remodeling, PI, notably
PI(4,5)P2, and PEmetabolism and DHA bioavailability appear to
culminate in catastrophic remodeling of the synapse, mechanisti-
cally linked to vesicular depletion, impaired receptor trafficking,
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and morphological dendritic deformation. It will be essen-
tial to test whether intervention into one or more of these
metabolic pathways can delay conversion from pre-symptomatic
to symptomatic AD in the face of ongoing Aβ42 and tau
pathology. A better understanding of how cellular bioactive
lipids alter susceptibility to driving AD pathologies represents
a new, potentially transformative, means of identifying and
targeting metabolic determinants of Aβ susceptibility and, in
the long-term, an exciting means of potentially promoting AD
resistance.
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